The Novel Immune Checkpoint GPR56 Is Expressed on Tumor-Infiltrating Lymphocytes and Selectively Upregulated upon TCR Signaling

SIMPLE SUMMARY: Despite the clinical efficacy of so-called immune checkpoint inhibitors (ICIs) in various cancers, some cancer types, including epithelial ovarian cancer (EOC), do not effectively respond to current therapeutics. Thus, the identification of new immune checkpoints that regulate T cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilemjian, Vrouyr, Vlaming, Martijn R., Álvarez Freile, Jimena, Huls, Gerwin, De Bruyn, Marco, Bremer, Edwin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264967/
https://www.ncbi.nlm.nih.gov/pubmed/35804934
http://dx.doi.org/10.3390/cancers14133164

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264967/
https://www.ncbi.nlm.nih.gov/pubmed/35804934
http://dx.doi.org/10.3390/cancers14133164

Ejemplares similares